INTRODUCTION
Ceruloplasmin (Cp) is a 132 kDa copper protein that is abundant in serum (1) .
Several lines of evidence suggest that the ceruloplasmin (Cp) has an important role in iron metabolism. First, Cp catalyzes the conversion of Fe 2+ to Fe 3+ and is the major ferroxidase in plasma. This function is thought to be critical for loading of iron into apo-transferrin (2) . Second, Cp is likely to be important in iron transport and homeostasis. A role of Cp in iron release from cells and tissues has been suggested by early "organ culture" studies (3, 4) , and by recent findings of iron deposits in hereditary Cp deficiency patients (5) and in mice with targeted disruption of the Cp gene (6) . In contrast, studies in yeast have revealed that a Cp homologue, fet3p, is required for iron uptake into cells (7, 8) , and we have shown that Cp stimulates iron uptake by iron-deficient cells of hepatic and erythroid origin (9, 10) .
A major function of Cp may be to facilitate the "net flux" of iron between cells and tissues.
Iron status influences the expression of multiple iron-related genes (11) . Thus, the final evidence that Cp is involved in iron metabolism comes from observations that alterations in serum iron status are often accompanied by changes in serum Cp (and copper). This observation was first made by Warburg and Krebs (12) who showed that bleeding birds to make them iron-deficient resulted in a 3-to 6-fold increase in protein-bound copper in plasma. Similar observations have been made in humans: elevated levels of serum copper are observed in anemia due to massive hemorrhage (13) , dietary iron deficiency (14) , infection or inflammation (15) , and pregnancy (16) . After the discovery that Cp was the primary copper protein in blood (17) , the increase in serum copper was shown to be due to elevated serum Cp in dietary iron deficiency anemia (18, 19) , hemorrhagic anemia (20) , sickle cell disease (21) , renal failure (22) , anemia of inflammation (23) (24) (25) , and anemia asso-ciated with pregnancy (26) . While the Cp increase in anemia due to pregnancy and inflammation may be influenced by hormone and cytokine levels, the observations on dietary anemia and hemorrhage provide evidence for a direct relationship between iron deficiency and plasma Cp levels.
Despite abundant in vivo evidence that serum Cp increases during anemia, little is known about the underlying molecular mechanism(s). The liver is the major source of plasma Cp in adults (27, 28) , and we have shown that treatment of cultured human hepatocarcinoma HepG2 or Hep3B cells with iron chelators markedly increases Cp gene expression and protein synthesis (9) . We have also shown that the increase in Cp mRNA is not due to increased transcript stability, but rather is due to an increase in the rate of transcription as demonstrated by nuclear "run-on" experiments (9) . There are at least two known mechanisms by which cellular iron deficiency increases gene transcription. Iron-deficiency in Saccharomyces cerevisiae activates the AFT1 transcription factor which in turn up-regulates the entire iron regulon including the Cp homologue and ferroxidase, FET3 (29) ; however, a vertebrate homologue of AFT1 has not yet been identified. In vertebrate cells, iron deficiency has been shown to activate hypoxia-inducible factor-1 (HIF-1), a heterodimeric transcription factor complex.
HIF-1 consists of the helix-loop-helix (HLH)/PAS proteins HIF-1α and HIF-1β (identical to aryl hydrocarbon nuclear translocator [ARNT]) (30) . HIF-1α is the key regulatory component of the complex since it is absent under normal conditions, but is upregulated by the iron chelator desferrioxamine (and by hypoxia and CoCl 2 ). In contrast HIF-1β expression is essentially constitutive, and is promiscuous with respect to downstream targets, interacting with several HLH/PAS in addition to HIF-1α. Upon activation, the HIF-1α/HIF-1β dimer binds to hypoxiaresponsive elements (HRE) in multiple genes, including several with important functions in iron metabolism, e.g., erythropoietin (Epo) (31), heme oxygenase-1 (32), transferrin (33) , and transferrin receptor (34, 35) . We here report studies to elucidate the molecular mechanism(s) underlying transcriptional activation of Cp by iron deficiency in hepatic cells, and report an important role for HIF-1. 
EXPERIMENTAL PROCEDURES

Cell Lines and Culture Conditions-Human hepatoma cell lines Hep3B and
HepG2 were from American Type Culture Collection and were cultured in Dulbecco's modified Eagle's medium (Sigma). Mouse hepatoma cell lines Hepa1c1c7 and Hepa c4 were kind gifts of Oliver Hankinson and were cultured in modified Eagle's medium. All media were supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM Lglutamine (Life Technologies). All experiments were done with cells at 50 to 60% confluence. For most experiments, cells were maintained in a humidified atmosphere containing 5% CO 2 at 37 °C. For experiments involving hypoxia, oxygen tension in the hypoxia chamber (Billups-Rothenberg, San Diego, CA) was set at either 20% O 2 , v/v, for normoxic treatment, or 1% O 2 , v/v, for hypoxic treatment.
RNA Blot Analysis-RNA was isolated from HepG2 or Hep3B cells using Trizol reagent (GibcoBRL) according to company's protocol. Total RNA (20 µg) was denatured in formamide/formaldehyde and electrophoresed through a 1% agarose gel containing 6% formaldehyde, and was blotted on to nylon membranes (Schleicher and Schuell, Keene, NH). After cross-linking with ultraviolet light (Stratalinker, Stratagene), the filters were subjected to hybridization with a 646-base pair, Bst X1 
Construction of Vectors Containing Cp Promoter/Enhancer Fragments-Cp pro-
moter/enhancer constructs, engineered to contain Sac1 and Xho 1 restriction sites, were made by PCR amplification using pfu polymerase (Stratagene), primers containing these restriction site, and pGEM-Cp as template. The constructs were ligated into Sac1 and Xho 1 sites of pGL3basic or pGL3prom vectors (Promega). For the long constructs inserted into pGL3basic, the PCR products from two separate amplification reactions were ligated to form a single construct.
In brief, a proximal construct was made from -2389 (just 5'-upstream of an Eco R1 site) to -1 (the nucleotide upstream of the translation-initiation site which is here defined as +1). Several distal constructs were PCR-amplified from 5'-termini at -4774, -3789, -3639, and -3576 to the 3'-terminus at -2325. The proximal and distal products were ligated at the Eco R1 site, and then into the 5'-Sac1 and 3'-Xho 1 sites upstream of luciferase in pGL3basic. Other constructs were made by PCR amplification of pGEM-Cp between -3639 and -3429 and between -3639 and -3544, and were ligated into the Sac 1 and Xho-1 sites of the pGL3prom vector upstream of the SV40 promoter and luciferase. Site-directed mutagenesis of the Cp HRE was done by the megaprimer method (38) . All deletion and mutation constructs were verified by sequencing. Preparation of Nuclear Extracts-Nuclear extracts were prepared from Hep3B, HepG2, Hepa-1c1c7, and Hepa c4 cells as described (33) . Briefly, 1 x 10 8 cells were washed twice with ice-cold phosphate-buffered saline and once with a solution containing 10 mM Tris-HCl, pH 7.8, 1.5 mM MgCl 2 , and 10 mM KCl, supplemented with a protease inhibitor cocktail containing 0.5 mM dithiothreitol, 0.4 mM phenylmethylsulfonyl fluoride, and 2 µg /ml each of leupeptin, pepstatin, and aprotinin (Sigma). After incubation on ice for 10 min, the cells were lysed by 10 strokes with a Dounce homogenizer, and the nuclei were pelleted and resuspended in a solution containing 420 mM KCl, 20 mM Tris-HCl, pH 7.8, 1.5 mM MgCl 2 , and 20% glycerol, supplemented with the protease cocktail described above, and incubated at 4 °C with gentle agitation. The nuclear extract was centrifuged at 10,000 g for 10 min, and the supernatant was dialyzed twice against a solution of 20 mM Tris-HCl, pH 7.8, 100 mM KCl, 0.2 mM EDTA, and 20% glycer-ol. Protein concentration was determined using the Bio-Rad reagent with bovine serum albumin as standard. The presence of consensus HIF-1 binding sites, i.e., G / A CGTG (46) , in the 5'-flanking region of human Cp was examined. Six consensus sites, arranged in three adjacent pairs, were found between positions -4774 and -2390 (Fig. 2B, left) .
Transient Transfection of Cells and
Electrophoretic Mobility Shift Assay (EMSA)-Sequences
RESULTS
Regulation of Cp Gene Expression by HIF-1 Agonists-
To determine the activity of these sites, a series of promoter/enhancer fragments was constructed with progressively larger 5'-deletions, and the fragments ligated upstream of luciferase in the promoterless reporter gene pGL3basic. Hep3B cells transfected with a construct in which the upstream pair of consensus HIF-1 binding was removed (Cp -3789, -1 -Luc) were still activated by iron chelators or by CoCl 2 (Fig. 2B, right) . However, transfection of cells with a construct lacking the three Specific formation of a radiolabeled complex was observed in cells treated with hypoxia or iron chelators, but not in untreated cells (Fig. 3A) . Constitutive and non-specific bands of greater electrophoretic mobility were seen as previously reported for the Epo and other HREs (49) . As a positive control, extracts from untreated and hypoxic Hep3B cells were incubated with a radiolabeled probe containing the HRE of human Epo; a hypoxia-inducible complex was seen with electrophoretic mobility similar to that observed with the Cp probe. Essentially identical results with Cp were obtained with nuclear extracts from HepG2 cells (not shown). Competition experiments were done to show the specificity of binding of the complex to the Cp HRE probe. The binding of radiolabeled Cp HRE probe to the HIF-1 complex in nuclear extracts from hypoxic Hep3B cells was effectively competed by a 100-fold molar excess of unlabeled Cp HRE probe (Fig. 3B) . However, unlabeled competitor probe containing a mutation in the HIF-1 binding site was ineffective even at 1000-fold molar excess. As a positive control, an unlabeled Epo HRE probe was found to be an effective competitor, although perhaps with a lower efficiency than the Cp HRE. Gel "supershift" studies were done to identify components of the nuclear extract complex that binds to the Cp HRE probe. A rabbit monoclonal antibody against HIF-1α shifted the mobility of the complex induced by desferrioxamine DNA-protein binding (Fig. 3C) . Furthermore, a polyclonal (Fig. 4A) . Essentially identical results were obtained with a construct containing only the active Cp HRE inserted before the SV40 promoter driving luciferase (Cp -3639, -3544 -SV40-Luc) (Fig. 4B) . To further investigate the specificity of HIF-1 binding to the Cp enhancer we examined the binding of transcription factor complexes to the Cp HRE in ARNT/HIF-1β-deficient cells. Binding of the HIF-1 complex to the probe was observed in nuclear extracts made from wild-type Hepa-1c1c7 cells treated with iron chelators or CoCl 2 ; however, essentially no HIF-1 binding was seen in the ARNT/HIF-1β-deficient cells (Fig. 4C ).
Together these results clearly demonstrate the requirement for HIF-1 in activa- The sequence elements required for HIF-1 activation of the Epo gene, the archetype HIF-1-responsive gene, include a core G / A CGTG sequence, a downstream CACAG sequence, followed by two consensus HNF-4 binding sites (Fig. 5A) . The Cp HRE, like all known HIF-1-responsive elements (46) , also contains the critical G / A CGTG core sequence (see Fig. 5B for examples) . In addition, the Cp HRE contains the consensus "CACAG" site present in Epo and most, but not all (e.g., The genes activated by HIF-1 can be classified into three functional groups. In one group are proteins that increase tissue oxygen delivery by their systemic participation in erythropoiesis, e.g., transferrin (33) , transferrin receptor (34, 35) , heme oxygenase-1 (32), and erythropoietin (31) . The second group contains proteins that increase local oxygen delivery to tissues via modification of blood vessel relaxation and development, e.g., inducible nitric oxide synthesis (51) and vascular endothelial growth factor (VEGF) (52, 53) . Heme oxygenase-1 produces the potent vasodilator carbon monoxide and may belong to this group in addition to the first. The third group contains proteins that do not alter tissue oxygen delivery, but rather are necessary for adaptation of cellular metabolism under conditions of low oxygen, e.g., glucose transporter-1 (54) and most glycolytic enzymes (55) . At this time we can only speculate about the functional group in which Cp belongs. Much experimental evidence suggests that Cp is a member of the first group, i.e., an enhancer of erythropoiesis. First, early studies showed that copper deficiency causes anemia in animals, implicating a copper protein as an important "catalyst for hemoglobin formation" (56, 57) . The role for Cp in erythropoiesis is supported by recent findings in patients with hereditary Cp deficiency who, in general, have microcytic, hypochromic anemia and below-normal hemoglobin level (58) (59) (60) . The studies with patients have not been confirmed in studies of mice with a disrupted Cp gene in which plasma hemoglobin levels were normal (6) . Finally, a role of Cp in erythropoiesis has been shown directly in aplastic anemia patients; injection of purified Cp rapidly and dramatically increases both reticulocyte number and hemoglobin level (61) . To our knowledge, Cp is the first positive acute phase reactant protein shown to be regulated by HIF-1 activation. Transferrin is activated by HIF-1 (33) but is a negative acute phase protein. Several (but not all) positive acute phase proteins, e.g., α 1 -antitrypsin, α 1 -antichymotrypsin, complement C3, haptoglobin, and α 1 -acid glycoprotein are activated by hypoxia, but the specific role of HIF-1 has not been determined (62) . Thus, Cp may represent a new functional group of HIF-1 effector proteins, a subset of the proinflammatory acute phase proteins.
Our findings are consistent with many reports that plasma Cp (and copper) is elevated during multiple conditions of anemia including dietary iron deficiency (18, 19) , hemorrhage (20) , sickle cell disease (21), renal failure (22) , pregnancy (26) , and anemia of inflammation (23) (24) (25) . The importance of HIF-1 activation in transcriptional regulation of liver Cp synthesis would suggest that pathological conditions featuring chronic hypoxia will also activate HIF-1, and thus should increase serum Cp. In fact, in patients with various chronic obstructive pulmonary diseases, e.g., chronic bronchitis and asthma, serum Cp is increased by 35% to 100% compared to controls (63) (64) (65) . The response is not due to a generalized acute phase response since elevated Cp is not found in a control group of cigarette smokers without pulmonary dysfunction, and since two other acute phase reactants, haptoglobin and orosomucoid, are unchanged (63) . In studies of healthy young adults, hypoxia induced by exposure to high altitude also significantly increases serum Mukhopadhyay, C.K. et al. Figure 3 HIF-1 
